An Open Label Study to Investigate the Maximum Tolerated Dose of RO5045337 in Patients With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL / SCLL)

Inclusion Criteria:

- Adult patients, >=18 years of age

- Acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia in
blast phase, refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma

- Relapsed or refractory to approved therapies, or no viable alternative therapy
available

- ECOG performance status of 0-2

Exclusion Criteria:

- Patients receiving any other agent or therapy to treat their malignancy

- Pre-existing gastrointestinal disorders which may interfere with absorption of drugs

- Clinically significant cardiovascular disease

- Pregnant or lactating women

- HIV-positive patients receiving combination antiretroviral therapy

- Amendment J and onward for patients in the food effect evaluation and for all
subsequent patients if dosing with a high fat/high calorie meal is found to be
optimal: Patients with allergies to any ingredient in the defined liquid supplement
and/or inability to tolerate a high fat/high calorie meal twice daily on scheduled
RO5045337 dosing days